Table 1 Studies on allo-SCT versus... | American Society of Hematology

Table 1

Studies on allo-SCT versus chemotherapy in pediatric newly diagnosed AML with analysis according to the intention-to-treat principle

Group/study/patients	Period	Indication for allo-SCT in CR1	Age, y	Percentage of EFS/% of DFS	OS, %	With donor, %	Underwent allo-SCT, %	TRM, %
AML BFM 98 + Interim98⁵⁰	July 1998 to March 2004	HR patients n = 275 (CR)	< 18	5-y DFS (P = .52)	5-y OS (P = .16)	23	13
Total, n = 494
Donor, n = 63				47 ± 7	58 ± 9			3
No donor, n = 188				43 ± 4	56 ± 4			4
POG8821^7,26	1988-1993	All patients	≤ 21	3-y EFS	3-y OS	16*	14†	P = .005
Total, n = 321
Allo-SCT, n = 89				52 ± 8	Not given			Not given
Auto-SCT, n = 115				38 ± 6 (P = .01)	Lower than allo-SCT (P = .007)			15
Chemo, n = 117				36 ± 6 (P = .06)	Similar to allo-SCT (P = .15)			2.7
CCG 2891^6,7	October 1989 to April 1995	All patients	< 21	8-y DFS (chemo vs allo, P = .01)	8-y OS (chemo vs allo, P = .05)	28*	19†
Total, n = 537
Allo-SCT, n = 181				55 ± 9	60 ± 9			14
Auto-SCT, n = 177				42 ± 8	48 ± 8			5
Chemo, n = 179				47 ± 8	53 ± 8			4
CCG-251, -213, -2861, -2891, and -2941¹⁶	1979-1996	All patients	< 21	8-y DFS (P = .005)	8-y OS (P = .026)	25*	Not given	P < .001
Total, n = 1464
Allo-SCT, n = 373				47 ± 6	54 ± 6			17 ± 4
No donor, n = 1091				37 ± 4	45 ± 4			7 ± 2
CCG 2961¹⁷	August 1996 to March 2002	All patients	< 21	5-y DFS (P = .021)	5-y OS (P = .425)	27*	Not given	P = .007
Total, n = 633
Donor, n = 170				60 ± 8	67 ± 8			8
No donor, n = 463				50 ± 5	62 ± 5			3
EORTC-CLG 58921²⁰	June 1993 to December 2000	All patients	< 18	5-y DFS	5-y OS	22†	19†
Total, n = 145
Donor, n = 39				63 ± 8	78 ± 7			8
No donor, n = 106				57 ± 5	65 ± 5			5
UK-MRC AML 10^4,32	May 1988 to March 1995	All patients	< 14	Not given	10-y OS (P = .3)	28†	20†	P = .001
Total, n = 315
Donor, n = 85					68			9
No donor, n = 230					59			1‡

Group/study/patients	Period	Indication for allo-SCT in CR1	Age, y	Percentage of EFS/% of DFS	OS, %	With donor, %	Underwent allo-SCT, %	TRM, %
AML BFM 98 + Interim98⁵⁰	July 1998 to March 2004	HR patients n = 275 (CR)	< 18	5-y DFS (P = .52)	5-y OS (P = .16)	23	13
Total, n = 494
Donor, n = 63				47 ± 7	58 ± 9			3
No donor, n = 188				43 ± 4	56 ± 4			4
POG8821^7,26	1988-1993	All patients	≤ 21	3-y EFS	3-y OS	16*	14†	P = .005
Total, n = 321
Allo-SCT, n = 89				52 ± 8	Not given			Not given
Auto-SCT, n = 115				38 ± 6 (P = .01)	Lower than allo-SCT (P = .007)			15
Chemo, n = 117				36 ± 6 (P = .06)	Similar to allo-SCT (P = .15)			2.7
CCG 2891^6,7	October 1989 to April 1995	All patients	< 21	8-y DFS (chemo vs allo, P = .01)	8-y OS (chemo vs allo, P = .05)	28*	19†
Total, n = 537
Allo-SCT, n = 181				55 ± 9	60 ± 9			14
Auto-SCT, n = 177				42 ± 8	48 ± 8			5
Chemo, n = 179				47 ± 8	53 ± 8			4
CCG-251, -213, -2861, -2891, and -2941¹⁶	1979-1996	All patients	< 21	8-y DFS (P = .005)	8-y OS (P = .026)	25*	Not given	P < .001
Total, n = 1464
Allo-SCT, n = 373				47 ± 6	54 ± 6			17 ± 4
No donor, n = 1091				37 ± 4	45 ± 4			7 ± 2
CCG 2961¹⁷	August 1996 to March 2002	All patients	< 21	5-y DFS (P = .021)	5-y OS (P = .425)	27*	Not given	P = .007
Total, n = 633
Donor, n = 170				60 ± 8	67 ± 8			8
No donor, n = 463				50 ± 5	62 ± 5			3
EORTC-CLG 58921²⁰	June 1993 to December 2000	All patients	< 18	5-y DFS	5-y OS	22†	19†
Total, n = 145
Donor, n = 39				63 ± 8	78 ± 7			8
No donor, n = 106				57 ± 5	65 ± 5			5
UK-MRC AML 10^4,32	May 1988 to March 1995	All patients	< 14	Not given	10-y OS (P = .3)	28†	20†	P = .001
Total, n = 315
Donor, n = 85					68			9
No donor, n = 230					59			1‡

CLG indicates Children Leukemia Group; and UK-MRC, United Kingdom Medical Research Council.

Percentage calculated from patients who achieved CR and are eligible for random assignment.

†

Percentage calculated from total group of patients.

‡

Three deaths, 1 after auto-SCT and 2 after MUD

View Large

This Feature Is Available To Subscribers Only